Tuesday, November 13, 2012
Its main competition is seeking approval of a treatment for the lung disease COPD, but the leaders of Pearl Therapeutics Inc., and investors who just ponied up $65 million to push the company’s own COPD drug into Phase III trials, are unbowed.
Monday, November 12, 2012
|Dr. Tony Fauci.|
|Patrizia Fanara and David Fineman of KineMed.|
Wednesday, November 7, 2012
Tuesday, November 6, 2012
Monday, November 5, 2012
Cancer drug maker Pharmacyclics Inc.’s stock dropped almost 20 percent at one point Monday, after it released disappointing trial data.
Pharmacyclics announced that a group of multiple myeloma patients it was testing its drug on did not experience tumor shrinkage. According to the Associated Press, the company will now try testing it in higher doses and in combination with other drugs.
|Pharmacyclics CEO Robert Duggan and CEO Maky Zanganeh.|
|BioMarin CEO Jean-Jacques Bienaime.|
Friday, November 2, 2012
|BNBuilders' David Becker (left) and Sean Truesdale.|
|Genentech co-founder Herb Boyer.|
Box checked, move on to other things and the phrase quietly floats away.
Thursday, November 1, 2012
|Portola CEO Bill Lis.|
Diagnostic test developer Advanced Cell Diagnostics Inc. completed a $12 million Series B financing, led by New Leaf Venture Partners.
Wednesday, October 31, 2012
BioMarin licenses North American rights to rare disease drug, invests $5M in Catalyst Pharmaceutical Partners
Tuesday, October 30, 2012
Monday, October 29, 2012
|Bluebird Bio's David Davidson.|
Sunday, October 28, 2012
Faking out a key player linked to amyotrophic lateral sclerosis could provide a new game plan in drug researchers’ battle against the deadly disorder also known as Lou Gehrig’s disease, according to scientists at the Gladstone Institutes and Stanford University.
Wednesday, October 24, 2012
Tuesday, October 23, 2012
Monday, October 22, 2012
Friday, October 12, 2012
What’s good for Google and a growing number of employers is good for Genentech — and for gay and lesbian employees and their partners. Starting Jan. 1, the South San Francisco-based biotech giant will “gross up” the pay of employees with same-sex partners to cover the taxes that the Internal Revenue Service grabs for company-provided medical benefits to families and the like. The IRS does not tax company benefits received by opposite-sex spouses. But federal tax law does not extend equivalent treatment to same-sex spouses.
Wednesday, October 10, 2012
Private equity firm Longitude Capital closed a fund that will invest in the life sciences after raising $385 million for it. This fund, Longitude Venture Parnters II LP, will invest in drug development and medical technology. The firm had hoped to raise at least $325 million for it.
Tuesday, October 9, 2012
Monday, October 8, 2012
Shinya Yamanaka, the Japanese scientist who reprogrammed mature mouse cells so they could be manipulated to become any type of cell, was named the 2012 winner of the Nobel Prize for physiology or medicine. Yamanaka works part time at the Gladstone Institutes in San Francisco.
Friday, October 5, 2012
Sartorius Stedim SUS Inc., which makes sturdy, IV-like, single-use bags used by drug manufacturers, is closing its Concord plant beginning this month and moving operations to an expanded facility in Puerto Rico. Ninety-one people will lose their jobs in the move, with the first wave expected this month, according to an August letter from the company to Stephen Bailer, executive director of the Workforce Development Board of Contra Costa County. The plant closing process will be completed by the end of April 2013. "We have a great workforce there and we're lucky to have such a committed, long-tenured team," said Sartorius President Mary Lavin in New York. "But we needed to expand."
GlaxoSmithKline has stopped work on a compound from Anacor Pharmaceuticals Inc. after finding resistance among a "small number" of patients in a mid-stage trial in complicated urinary tract infections, Palo Alto-based Anacor said Friday.
A “smart bomb” that targets breast cancer cells while minimizing collateral damage to healthy cells is pushing Genentech Inc. toward its fourth cancer drug approval in 18 months. Trastuzumab emtansine, or T-DM1, which the South San Francisco-based U.S. subsidiary of drug giant Roche AG submitted to the Food and Drug Administration in August, could be approved by the end of February. That timeline is good news for patients, some of whom have pushed the FDA to speed approval of the drug, which piggybacks a chemotherapy agent by ImmunoGen Inc. onto Genentech’s long-running cancer drug Herceptin.
Thursday, October 4, 2012
BioSeek LLC, a South San Francisco biotechnology company, has won a new $46.7 million,contract from the U.S. Environmental Protection Agency to study the potential impacts of environmental chemicals, pesticides, "failed pharmaceuticals, and nanomaterials" on human health. The private company and the EPA separately announced the five-year contract, worth up to $46.7 million, depending on the volume of testing required.
Wednesday, October 3, 2012
|GO-Biz executive director Rish Kajan.|
San Francisco’s surging biotech industry feeds off a network of research institutions, but lease rates and city red tape remain obstacles to growth, according to a report unveiled Wednesday at the San Francisco Chamber of Commerce's “ForecastSF” event. The report, prepared by San Francisco State University associate professor of economics Philip King for the Hospital Council of Northern and Central California, found that hospital and biomedical spending in San Francisco totals $16.7 billion and is responsible for more than 104,000 jobs, or almost one in five jobs in the city. Mayor Ed Lee called the industry a “sleeping giant.” But the giant is restless, according to the report.
Monday, October 1, 2012
Friday, September 28, 2012
Alameda diagnostic test developer Singulex Inc. filed for an $86.25 million initial public offering Friday, promising a test to measure signs of heart disease at previously undetectable levels. Using the Jumpstart Our Business Startups, or JOBS, Act to qualify as an "emerging growth company," 15-year-old Singulex said in a filing with the Securities and Exchange Commission that its technology helps to earlier detect and monitor biomarkers of heart attacks, heart failure, stroke and other heart diseases.
Former Exelixis Inc. business development chief Fran Heller will join Bristol-Myers Squibb Co. as senior vice president of business development, the company said Friday.
Elan Corp. will shutter its South San Francisco drug discovery operations as it shifts the work into a new publicly held company. The Irish biotech company (NASDAQ: ELN), which this summer saw a high-profile experimental Alzheimer's drug crash in late-stage clinical trials, will have no drug discovery or preclinical drug development programs by Dec. 31, it said in a Securities and Exchange Commission filing this week. Closing the South San Francisco facilities, where most of Elan's roughly 400 employees are housed, will translate into $160 million to $180 million in employee severance costs, facilities costs and other restructuring charges, according to the Tuesday filing.
|Rigel's Don Payan (left) and Raul Rodriguez.|
AvidBiotics Corp.’s got a beef with its freshly minted multimillion-dollar deal with DuPont — and if things go as the small South San Francisco biotech company plans, it will have chicken and vegetables as well. AvidBiotics inked the deal Sept. 17 with DuPont’s health and nutrition business to develop a targeted protein to kill a strain of Escherichia coli, or E. coli, in meat processing plants. DuPont gave AvidBiotics upfront cash, took a minority stake in the eight-employee company and will pay all research and development costs.
Mission Bay roars to life: Biotechs, UCSF, residential developers jostle for space in S.F.'s newest neighborhood
|QB3's Reg Kelly.|
|Allopartis CEO Robert Blazej.|
Thursday, September 27, 2012
Medical products maker Abaxis Inc. will get $17.25 million in a settlement with Cepheid Inc. Sunnyvale-based Cepheid (NASDAQ: CPHD) will pay the money to Union City-based Abaxis (NASDAQ: ABAX) without admitting wrongdoing, but to "terminate all pending and future claims connected with the litigation." The dispute, in which both companies made claims and counterclaims, concerned several patents held by Abaxis over reagent and chemical compositions and processes.